{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:02:10Z","timestamp":1790949730176,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study aimed to investigate the association between a new biomarker that incorporates albumin (Alb) and butyrylcholinesterase (BCHE) levels, as well as the prognosis of hepatocellular carcinoma (HCC) after hepatectomy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study enrolled 1712 patients who underwent primary hepatectomy for HCC between January 2003 and December 2019 at seven institutions belonging to the Hiroshima Surgical Study Group of Clinical Oncology. The entire dataset was randomly split into discovery and validation cohorts in a 7:3 ratio. The product of the preoperative Alb and BCHE levels was defined as the ABC. In the discovery cohort, the patients in the high-ABC group (\u2265\u2009951) were compared with those in the low-ABC group (&lt;\u2009951). These findings then were confirmed in the validation cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the discovery cohort, a significant difference was observed in the 5-year survival rate between the high- and low-ABC groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and ABC was identified as an independent prognostic factor for HCC. Similarly, in the validation cohort, a significant difference was observed in the 5-year survival rate between the high- and low-ABC groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and ABC was identified as an independent prognostic factor for HCC. Furthermore, in the discovery and validation cohorts, significant differences in the early recurrence rate between the two groups were observed (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.020, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>For patients with HCC, ABC is a useful predictive biomarker because it can be calculated in a simple manner and because it provides accurate prognostic information.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-024-16650-6","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:38:17Z","timestamp":1733859497000},"page":"1973-1984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Albumin\u2013Butyrylcholinesterase as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology"],"prefix":"10.1245","volume":"32","author":[{"given":"Takeshi","family":"Tadokoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7364-1798","authenticated-orcid":false,"given":"Tsuyoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhiko","family":"Honmyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Oshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Onoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Kohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ohdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"16650_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410\u201320.","journal-title":"JAMA Surg."},{"key":"16650_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/SLA.0000000000000747","volume":"261","author":"JH Shim","year":"2015","unstructured":"Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939\u201346.","journal-title":"Ann Surg."},{"key":"16650_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/nu13030761","volume":"13","author":"D Meza-Valderrama","year":"2021","unstructured":"Meza-Valderrama D, Marco E, D\u00e1valos-Yerovi V, et al. Sarcopenia, malnutrition, and cachexia: adapting definitions and terminology of nutritional disorders in older people with cancer. Nutrients. 2021;13:761.","journal-title":"Nutrients."},{"key":"16650_CR4","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.1038\/s41598-021-88254-z","volume":"11","author":"H Kanno","year":"2021","unstructured":"Kanno H, Goto Y, Sasaki S, et al. Geriatric nutritional risk index predicts prognosis in hepatocellular carcinoma after hepatectomy: a propensity score-matching analysis. Sci Rep. 2021;11:9038.","journal-title":"Sci Rep."},{"key":"16650_CR5","doi-asserted-by":"publisher","first-page":"4796598","DOI":"10.1155\/2019\/4796598","volume":"2019","author":"GY Lv","year":"2019","unstructured":"Lv GY, An L, Sun DW. Geriatric nutritional risk index predicts adverse outcomes in human malignancy: a meta-analysis. Dis Markers. 2019;2019:4796598.","journal-title":"Dis Markers."},{"key":"16650_CR6","doi-asserted-by":"publisher","first-page":"86573","DOI":"10.18632\/oncotarget.13472","volume":"7","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Xu P, Kang H, et al. Prognostic nutritional index as a prognostic biomarker for survival in digestive system carcinomas. Oncotarget. 2016;7:86573\u201383.","journal-title":"Oncotarget."},{"key":"16650_CR7","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1080\/01635581.2022.2059091","volume":"74","author":"J Chen","year":"2022","unstructured":"Chen J, Song P, Peng Z, et al. The controlling nutritional status (CONUT) score and prognosis in malignant tumors: a systematic review and meta-analysis. Nutr Cancer. 2022;74:3146\u201363.","journal-title":"Nutr Cancer."},{"key":"16650_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1055\/a-2091-2072","volume":"55","author":"X Xu","year":"2023","unstructured":"Xu X, Kang F, Zhang N, Niu Y, Jia J. Geriatric nutritional risk index and the survival of patients with hepatocellular carcinoma: a meta-analysis. Horm Metab Res. 2023;55:692\u2013700.","journal-title":"Horm Metab Res."},{"key":"16650_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.hpb.2018.03.019","volume":"20","author":"Z Man","year":"2018","unstructured":"Man Z, Pang Q, Zhou L, et al. Prognostic significance of preoperative prognostic nutritional index in hepatocellular carcinoma: a meta-analysis. HPB Oxford. 2018;20:888\u201395.","journal-title":"HPB Oxford."},{"key":"16650_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12876-019-1126-6","volume":"19","author":"K Takagi","year":"2019","unstructured":"Takagi K, Domagala P, Polak WG, Buettner S, Ijzermans JNM. Prognostic significance of the controlling nutritional status (CONUT) score in patients undergoing hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19:211.","journal-title":"BMC Gastroenterol."},{"key":"16650_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12876-021-01944-w","volume":"21","author":"YC Tsai","year":"2021","unstructured":"Tsai YC, Sou FM, Liu YW, et al. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol. 2021;21:386.","journal-title":"BMC Gastroenterol."},{"key":"16650_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.21037\/atm.2020.02.85","volume":"8","author":"S Zhao","year":"2020","unstructured":"Zhao S, Wang M, Yang Z, et al. Comparison between Child\u2013Pugh score and albumin\u2013bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med. 2020;8:539.","journal-title":"Ann Transl Med."},{"key":"16650_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MPA.0b013e31815b6b2b","volume":"36","author":"S Mitsunaga","year":"2008","unstructured":"Mitsunaga S, Kinoshita T, Hasebe T, et al. Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas. 2008;36:241\u20138.","journal-title":"Pancreas."},{"key":"16650_CR14","doi-asserted-by":"crossref","unstructured":"Gao H, Wan Y, Fan X, Dong Y, Ji X, Song W. The role of cholinesterase in differential diagnosis between gastric cancer and benign gastric diseases. Clinical Lab. 2021;67.","DOI":"10.7754\/Clin.Lab.2020.200525"},{"key":"16650_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00384-022-04119-5","volume":"37","author":"Y Takano","year":"2022","unstructured":"Takano Y, Haruki K, Tsukihara S, et al. The impact of low serum cholinesterase levels on survival in patients with colorectal cancer. Int J Colorectal Dis. 2022;37:869\u201377.","journal-title":"Int J Colorectal Dis."},{"key":"16650_CR16","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.21873\/anticanres.13217","volume":"39","author":"M Yamamoto","year":"2019","unstructured":"Yamamoto M, Saito H, Uejima C, et al. Combination of serum albumin and cholinesterase levels as prognostic indicator in patients ith colorectal cancer. Anticancer Res. 2019;39:1085\u201390.","journal-title":"Anticancer Res."},{"key":"16650_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol."},{"key":"16650_CR18","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85:1001\u20135.","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"16650_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82:777\u2013783.","journal-title":"Am J Clin Nutr."},{"key":"16650_CR20","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1245\/s10434-018-6672-6","volume":"25","author":"N Harimoto","year":"2018","unstructured":"Harimoto N, Yoshizumi T, Inokuchi S, et al. Prognostic significance of preoperative controlling nutritional status (CONUT) score in patients undergoing hepatic resection for hepatocellular carcinoma: a multi-institutional study. Ann Surg Oncol. 2018;25:3316\u201323.","journal-title":"Ann Surg Oncol."},{"key":"16650_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13539-012-0083-5","volume":"4","author":"L Santarpia","year":"2013","unstructured":"Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2013;4:31\u20139.","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"16650_CR22","doi-asserted-by":"publisher","first-page":"580800","DOI":"10.3389\/pore.2021.580800","volume":"27","author":"Y Bi","year":"2021","unstructured":"Bi Y, Zhang J, Zeng D, et al. Cholinesterase is associated with prognosis and response to chemotherapy in advanced gastric cancer. Pathol Oncol Res. 2021;27:580800.","journal-title":"Pathol Oncol Res."},{"key":"16650_CR23","first-page":"60","volume":"12","author":"S Takaki","year":"2020","unstructured":"Takaki S, Fukuhara T, Mori N, Tsuji K. High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate-stage hepatocellular carcinoma. Mol Clin Oncol. 2020;12:60\u20138.","journal-title":"Mol Clin Oncol."},{"key":"16650_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3892\/mco.2012.48","volume":"1","author":"H Takeda","year":"2013","unstructured":"Takeda H, Nishikawa H, Iguchi E, et al. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol. 2013;1:241\u20138.","journal-title":"Mol Clin Oncol."},{"key":"16650_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/bmm.15.28","volume":"9","author":"F Cacciatore","year":"2015","unstructured":"Cacciatore F, Della-Morte D, Basile C, et al. Butyryl-cholinesterase is related to muscle mass and strength: a new biomarker to identify elderly subjects at risk of sarcopenia. Biomark Med. 2015;9:669\u201378.","journal-title":"Biomark Med."},{"key":"16650_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00520-019-04717-0","volume":"28","author":"B Wang","year":"2020","unstructured":"Wang B, Thapa S, Zhou T, et al. Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia. Supportive Care. 2020;28:581\u20138.","journal-title":"Supportive Care."},{"key":"16650_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41598-022-27238-z","volume":"13","author":"Y Guo","year":"2023","unstructured":"Guo Y, Ren Y, Zhu L, Yang L, Zheng C. Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis. Sci Rep. 2023;13:934.","journal-title":"Sci Rep."},{"key":"16650_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.suronc.2015.12.002","volume":"25","author":"F Hirokawa","year":"2016","unstructured":"Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y, Uchiyama K. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol. 2016;25:24\u20139.","journal-title":"Surg Oncol."},{"key":"16650_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.14701\/ahbps.2018.22.4.335","volume":"22","author":"YH Lee","year":"2018","unstructured":"Lee YH, Koh YS, Hur YH, Cho CK, Kim HJ, Park EK. Effectiveness of the albumin\u2013bilirubin score as a prognostic factor for early recurrence after curative hepatic resection for hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg. 2018;22:335\u201343.","journal-title":"Ann Hepatobiliary Pancreat Surg."},{"key":"16650_CR30","first-page":"511","volume":"3","author":"H Soreq","year":"1991","unstructured":"Soreq H, Lapidot-Lifson Y, Zakut H. A role for cholinesterases in tumorigenesis? Cancer Cells. 1991;3:511\u20136.","journal-title":"Cancer Cells."},{"key":"16650_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cbi.2005.10.035","volume":"157\u20138","author":"CJ Vidal","year":"2005","unstructured":"Vidal CJ. Expression of cholinesterases in brain and non-brain tumours. Chem Biol Interact. 2005;157\u20138:227\u201332.","journal-title":"Chem Biol Interact."},{"key":"16650_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cancergencyto.2009.10.011","volume":"197","author":"CC Bernardi","year":"2010","unstructured":"Bernardi CC, Ribeiro Ede S, Cavalli IJ, Chautard-Freire-Maia EA, Souza RL. Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer. Cancer Genet Cytogenet. 2010;197:158\u201365.","journal-title":"Cancer Genet Cytogenet."},{"key":"16650_CR33","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1245\/s10434-020-08699-w","volume":"27","author":"F Hirokawa","year":"2020","unstructured":"Hirokawa F, Komeda K, Taniguchi K, et al. Is postoperative adjuvant transcatheter arterial infusion therapy effective for patients with hepatocellular carcinoma who underwent hepatectomy? A prospective randomized controlled trial. Ann Surg Oncol. 2020;27:4143\u201352.","journal-title":"Ann Surg Oncol."},{"key":"16650_CR34","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/j.1440-1746.2006.04790.x","volume":"22","author":"N Amaoka","year":"2007","unstructured":"Amaoka N, Osada S, Kanematsu M, Imai H, Tomita H, Tokuyama Y, et al. Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression. J Gastroenterol Hepatol. 2007;22:2202\u20137.","journal-title":"J Gastroenterol Hepatol."},{"key":"16650_CR35","doi-asserted-by":"publisher","first-page":"87202","DOI":"10.5493\/wjem.v14.i1.87202","volume":"14","author":"GR Sridhar","year":"2024","unstructured":"Sridhar GR, Gumpeny L. Emerging significance of butyrylcholinesterase. World J Exper Med. 2024;14:87202.","journal-title":"World J Exper Med."},{"key":"16650_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00008571-200305000-00005","volume":"13","author":"G Lando","year":"2003","unstructured":"Lando G, Mosca A, Bonora R, Azzario F, Penco S, Marocchi A, et al. Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study. Pharmacogenetics. 2003;13:265\u201370.","journal-title":"Pharmacogenetics."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16650-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:37:59Z","timestamp":1739194679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16650-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["16650"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16650-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The need for written informed consent was waived due to the retrospective nature of the study. An opt-out method for obtaining patient consent was used by all institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}